Novartis to acquire ocular gene therapy company Gyroscope Therapeutics
Novartis has agreed to acquire Gyroscope Therapeutics, a UK-based ocular gene therapy company, in a deal worth up to $1.5 billion. As per the terms of the deal, the Swiss pharma giant will pay $800 million upfront followed by up to $700 million in potential additional milestone payments. Through the deal, Novartis will gain access […]